Biocon posted improved quarterly earnings, supported by strong growth in its biosimilars business and healthy demand across key international markets. The company also benefited from operational improvements and better product mix during the quarter. Management reiterated its focus on expanding global partnerships and strengthening its biologics portfolio.
Analysts believe the biosimilars segment will remain the primary growth driver for Biocon as more products receive approvals in overseas markets. Investors will continue tracking product launches, regulatory approvals and export growth.
